Harvard Medical School
Dr. Jessica Lin is a medical oncologist specializing in the care of patients with thoracic malignancies. Dr. Lin received her MD from Harvard Medical School, Boston. After completing her residency in internal medicine at the Brigham and Women’s Hospital and fellowship in medical oncology at the Dana-Farber/Partners CancerCare program, she joined the faculty at Harvard Medical School and Massachusetts General Hospital Cancer Center. She has an active practice caring for patients in the Thoracic Oncology Program and the Henri and Belindar Termeer Center for Targeted Therapies.
The primary focus of Dr Lin’s research is to develop novel therapeutic and biomarker strategies for patients with advanced lung cancers. As a clinical investigator, she is deeply involved in clinical trials evaluating novel targeted therapies as well as combination strategies. Her translational research efforts are dedicated to the study of resistance mechanisms and exceptional responses to targeted therapies in molecularly defined subsets of lung cancer. The ultimate goal of her research is to improve outcomes for patients living with lung cancer.
Dr. Lin is a member of the International Association for the Study of Lung Cancer, American Association for Cancer Research, and American Society of Clinical Oncology.
14ner/Elevation Oncology (Individual(s) Involved: Self): Consultant, Consultant, Grant/Research Support, Grant/Research Support, institutional research fund, institutional research fund; BAYER (Individual(s) Involved: Self): Consultant, Consultant, Grant/Research Support, Grant/Research Support, institutional research fund, institutional research fund; Blueprint Medicines Corporation (Individual(s) Involved: Self): Consultant, Consultant; C4 Therapeutics (Individual(s) Involved: Self): Consultant, Consultant; Genentech/ Roche (Individual(s) Involved: Self): Advisory Board, Advisory Board, Grant/Research Support, Grant/Research Support; Hengrui Therapeutics (Individual(s) Involved: Self): Grant/Research Support, Grant/Research Support; Linnaeus Therapeutics (Individual(s) Involved: Self): Grant/Research Support, Grant/Research Support, institutional research funding, institutional research funding; Loxo Oncology (Individual(s) Involved: Self): Grant/Research Support, Grant/Research Support; Mirati Therapeutics (Individual(s) Involved: Self): Consultant, Consultant; Neon Therapeutics (Individual(s) Involved: Self): Grant/Research Support, Grant/Research Support; Novartis (Individual(s) Involved: Self): Consultant, Consultant, Grant/Research Support, Grant/Research Support, institutional research funding, institutional research funding; Nuvalent (Individual(s) Involved: Self): Consultant, Consultant, Grant/Research Support, Grant/Research Support, institutional research funding, institutional research funding; Pfizer (Individual(s) Involved: Self): Consultant, Consultant, Grant/Research Support, Grant/Research Support, Honorarium; institutional research funding, Honorarium; institutional research funding, Other Financial or Material Support, Other Financial or Material Support; Relay Therapeutics (Individual(s) Involved: Self): Grant/Research Support, Grant/Research Support, institutional research funding, institutional research funding; Turning Point Therapeutics (Individual(s) Involved: Self): Consultant, Consultant, Grant/Research Support, Grant/Research Support, institutional research fund, institutional research fund
Wednesday, August 24, 2022
12:05 PM – 1:20 PM
Wednesday, August 24, 2022
12:45 PM – 1:00 PM
Wednesday, August 24, 2022
1:00 PM – 1:20 PM
Wednesday, November 9, 2022
12:05 PM – 1:15 PM
Wednesday, November 9, 2022
12:10 PM – 12:30 PM
Wednesday, November 9, 2022
12:50 PM – 1:15 PM